Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2020 08:30 ET | Source: Celsion CORP

Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer

Excellent Surgical Response Noted at the Higher, 100 mg/m2 Dose Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...
May 15, 2020 08:00 ET | Source: Celsion CORP

Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update

Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J, May 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation...
May 08, 2020 09:00 ET | Source: Celsion CORP

Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020

LAWRENCEVILLE, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the first...
April 23, 2020 08:30 ET | Source: Celsion CORP

Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program

Added Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events Sale of an Additional $2.0 Million of NOL’s Expected in the 4th Quarter of 2020 ...
April 15, 2020 08:30 ET | Source: Celsion CORP

Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

Independent Data Monitoring Committee is Expected to Meet in July 2020 to Evaluate Overall Survival Data LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
March 26, 2020 08:00 ET | Source: Celsion CORP

Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm

Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage...
March 25, 2020 16:15 ET | Source: Celsion CORP

Celsion Corporation Reports 2019 Financial Results and Provides Business Update

Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020 LAWRENCEVILLE, N.J., March ...
March 23, 2020 08:00 ET | Source: Celsion CORP

Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency

Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading...
March 19, 2020 08:30 ET | Source: Celsion CORP

Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020

Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., March 19, 2020 (GLOBE NEWSWIRE) -- Celsion...
March 19, 2020 08:00 ET | Source: Celsion CORP

Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer

R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II...